Media ReleasesCellmid Limited

View All Cellmid Limited News

Cellmid Ltd, Completed CK3000 Diagnostic Study Results

-  Largest ever study of midkine in healthy volunteers – 574 individuals;
-  Results are pivotal in any regulatory submission for midkine diagnostics;
-  Elevated midkine predictive of serious illness in a small group of asymptomatic outliers.
SYDNEY, Wednesday 18 December 2013: Cellmid Limited (ASX:CDY) has completed its two year long CK3000 program investigating normal serum concentrations of midkine (MK) in the largest ever study of healthy volunteers involving 574 individuals.
The study results confirmed interim findings of “healthy” MK levels in a statistically meaningful population size and provided further insights into a small group of ‘outliers’, asymptomatic individuals presenting with elevated MK levels. The results are expected to be pivotal in future regulatory submission for stand alone midkine diagnostic tests for monitoring wellness, disease recurrence or treatment efficacy in any cancer.
For further information please download PDF below:
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.